Viatris Inc. (NASDAQ: VTRS) will present six abstracts on its investigational low-dose estrogen combined hormonal contraceptive weekly patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting from May 1-3 in Washington, D.C.

The presentations will include results from a Phase 3 study evaluating the contraceptive efficacy and safety of the company's investigational weekly patch. Additional data will cover the patch's adhesion profile under normal and extreme conditions, pharmacokinetic information, and cycle control data.

The U.S. Food and Drug Administration has accepted Viatris's New Drug Application for the investigational contraceptive patch under the 505(b)(2) regulatory pathway. The FDA assigned a target action date of July 30, 2026.

The application is supported by results from a multicenter, open-label, single-arm Phase 3 study that evaluated the safety and contraceptive efficacy of the patch. The study demonstrated what the company described as a favorable efficacy and safety profile with strong patch adhesion performance.

The investigational patch is being developed for women of childbearing potential with a BMI below 30 kg/m² who are candidates for combined hormonal contraception and prefer a non-invasive, reversible option with lower estrogen dosage.

Viatris currently markets Xulane, a contraceptive patch containing norelgestromin and ethinyl estradiol at 150/35 mcg per day. The company describes the investigational product as a lifecycle advancement of this existing patch.

The presentations at ACOG will be delivered through electronic poster sessions on Saturday, May 2, during two time slots: 8-9 a.m. EDT and 1:30-2:30 p.m. EDT.